<div><div></div><div>Annovis Bio entered into an Underwriting Agreement with Canaccord Genuity for a public offering of 7,895,000 shares and accompanying warrants to purchase up to 7,105,500 shares. The combined price is $1.90 per share with nine-tenths of a warrant, and the warrants are immediately exercisable at $2.25 per share for six years. Gross proceeds are expected to be approximately $15 million before expenses, with closing anticipated on May 21, 2026. Annovis plans to use the net proceeds to advance Buntanetap trials in Alzheimer's and Parkinson's and for working capital and general corporate purposes.Agreement details:<ul><li>Agreement type: Underwriting agreement for public equity and warrant offering</li><li>Counterparty: Canaccord Genuity</li><li>Signed / Effective: May 20 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Fund Buntanetap trials and bolster working capital and general corporate needs</li></ul>Original SEC Filing: Annovis Bio, Inc. [ ANVS ] - 8-K - May. 20, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

ANVS

Annovis Bio has launched a public offering of 7,895,000 shares and warrants underwritten by Canaccord Genuity, aiming to raise approximately $15 million. The shares are priced at $1.90 each, with warrants exercisable at $2.25 for six years. Proceeds will fund Buntanetap trials for Alzheimer's and Parkinson's, as well as general corporate needs. The offering is expected to close on May 21, 2026.

Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity